Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (APAP), Is Highlighted on a New Episode of "The Balancing Act" Airing on Lifetime TV
Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10
Evercore Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $7
Evercore ISI Remains a Buy on Savara (SVRA)